Pyxis Oncology (Pyxis Oncology) Cash-to-Debt : 5.59 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pyxis Oncology's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.59.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pyxis Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pyxis Oncology's Cash-to-Debt or its related term are showing as below:

PYXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.59 Med: 10.36 Max: 1665.06
Current: 5.59

During the past 5 years, Pyxis Oncology's highest Cash to Debt Ratio was 1665.06. The lowest was 5.59. And the median was 10.36.

PYXS's Cash-to-Debt is ranked worse than
52.4% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs PYXS: 5.59

Pyxis Oncology Cash-to-Debt Historical Data

The historical data trend for Pyxis Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pyxis Oncology Cash-to-Debt Chart

Pyxis Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1,312.67

10.36

1,665.06

9.48

5.59

Pyxis Oncology Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											9.48	7.38	6.71	6.15	5.59

Competitive Comparison of Pyxis Oncology's Cash-to-Debt

For the Biotechnology subindustry, Pyxis Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pyxis Oncology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pyxis Oncology's Cash-to-Debt falls into.

Pyxis Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pyxis Oncology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	119.298	/	(1.232	+	20.099)
	=	5.59

Pyxis Oncology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	119.298	/	(1.232	+	20.099)
	=	5.59

Pyxis Oncology (NAS:PYXS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pyxis Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pyxis Oncology (Pyxis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.pyxisoncology.com

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.

Executives

Pamela Ann Connealy	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane	officer: Chief Accounting Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan	director, officer: Chief Executive Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont	director	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin	other: Former Director	20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst	officer: Chief Scientific Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140